Skip to main content

Table 1 Characteristics of the study population

From: Impairment of endothelial function in Parkinson’s disease

  Parkinsonʼs disease Controls p-value
Number of subjects 41 41  
Male/female sex 24/17 (58.5%/41.5%) 24/17 (58.5%/41.5%) 1.0
Age (years) 65.4 ± 9.1 65.3 ± 10.7 0.947
BMI (kg/m2) 27.5 ± 4.8 27.5 ± 3.6 0.996
Arterial hypertension 20 (48.8%) 21 (51.2%) 0.825
Coronary heart disease 6 (14.6%) 6 (14.6%) 1.0
Diabetes mellitus 8 (19.5%) 7 (17.1%) 0.775
Dyslipidaemia 6 (14.6%) 8 (19.5%) 0.557
Smoking 6 (14.6%) 6 (14.6%) 1.0
RHI 1.8 ± 0.5 1.9 ± 0.5 0.478
Endothelial dysfunction 19 (46.3%) 14 (34.1%) 0.260
Hoehn and Yahr score 0, 2.5 (0–4.0)
Duration of PD since diagnosis (years) 0, 5.0 (0–15.0)
LED (mg) 900.0 (0–2280.0)
L-dopa 31 (75.6)
Dopamine agonists 25 (61%)
COMT inhibitors 18 (43.9)
MAO-B inhibitors 14 (34.1)
Amantadine 6 (14.6%)
  1. PD Parkinsonʼs disease, BMI body mass index, RHI reperfusion hyperemia index, PB blood pressure, LED levodopa equivalent dose, COMT catechol-O-methyl transferase, MAO-B monoamine oxidase